In its first national survey of US adults, the Pulmonary Fibrosis Foundation has found “alarmingly low” awareness of PF and its symptoms. To help combat late-stage diagnoses, the Pulmonary Fibrosis Foundation recently commissioned its first national survey of PF awareness among US citizens.* The...

The discovery of a new metabolic pathway has upended a long-held belief of how fibrosis occurs and offers hope for a new treatment target in PF. The results of a recent study point to new players in pulmonary fibrosis (PF) that may be important for a better understanding of the disease and developin...

Boehringer Ingelheim has announced that Canadians living with systemic sclerosis-associated ILD now have access to the pulmonary fibrosis medication OFEV (nintedanib) for slowing lung function decline. Health Canada has approved OFEV® (Nintedanib) as a treatment for Canadians living with systemic s...

Researchers at Stanford University School of Medicine have shown that immune cells from a blood sample are linked to worse outcomes in IPF. THE LANCET A study led by Stanford University School of Medicine has found a link between concentrations of a specific immune cell in the blood and poor disease...

Recently, international investigative teams discovered a novel way to potentially stop lung scarring. Science Translational Medicine Part of the body’s immune response to tissue injury, interleukin-11 (IL-11) is a signaling protein known to be involved in fibrosis (scarring) of the kidneys and hea...